106th Day Of Lockdown

Maharashtra2171211185589250 Tamil Nadu118594711161636 Delhi102831742173165 Gujarat37636267441978 Uttar Pradesh2996819627313 Telangana2761216287313 Karnataka2681511100417 West Bengal2383715790804 Rajasthan2140416575472 Andhra Pradesh211979745252 Haryana1799913645279 Madhya Pradesh1562711768622 Bihar12525933898 Assam12523833016 Odisha10097670354 Jammu and Kashmir89315399143 Punjab67494554175 Kerala5895345228 Chhatisgarh3415272814 Uttarakhand3230262143 Jharkhand3018210422 Goa190311568 Tripura171612481 Manipur14307710 Himachal Pradesh107876410 Puducherry104351714 Nagaland6443030 Chandigarh4924017 Arunachal Pradesh270922 Mizoram1971390 Sikkim125650 Meghalaya94432
Nation Current Affairs 19 Apr 2020 IISc to develop Covi ...

IISc to develop Covid-19 vaccine

DECCAN CHRONICLE. | AKSHEEV THAKUR
Published Apr 19, 2020, 4:05 pm IST
Updated Apr 20, 2020, 6:35 pm IST
The team estimates to develop the production technology in 8 months and start human clinical trial in a year
Representational Image. (AFP)
 Representational Image. (AFP)

The Indian Institute of Science (IISc) Molecular Biophysics Unit department will develop a vaccine for Covid-19. A team headed by Raghavan Varadarajan from the department will work on to develop a rapidly producible vaccine for protection to front-line health workers, senior citizens and individuals with co-morbidities such as cardiovascular disease and diabetes.

Going ahead with the previous studies on 2003 SARS-CoV virus, they have shown that that antibodies against the spike glycoprotein found on the surface of the earlier 2003 SARS-CoV virus inhibit viral infection in cell culture, and confer protection against infection in animal models.

 

"Hence, we and others are attempting to design and test variants of the spike glycoprotein of SARS-CoV-2 as vaccine candidates. Immunization with a vaccine should provide significant protection to individuals at high risk of aggravated illness upon infection. Previous studies have shown,"  the team states.

A number of spike protein derivatives have been designed and characterized at IISc. These are being tested in animal models through the IISc incubated start-up, Mynvax.

"The design which shows the best results in animals will be advanced to the development of production technology, safety and toxicity testing, followed by GMP manufacturing for use in Phase-1 clinical trials. We estimate that at least 100 million doses will be required to meet India’s requirement if the SARS-CoV-2 infection persists for the medium to long-term," the team explains.

The team estimates four months to identify a first-generation vaccine candidate, develop the production technology in eight months and start human clinical trial in a year.

...
Location: India, Karnataka, Bengaluru




ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT